Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Non-Muscle Invasive Bladder Cancer (NMIBC)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02009332
What this trial is testing

Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer

Who this might be right for
Non-muscle Invasive Bladder Cancer (NMIBC)
Aadi Bioscience, Inc. 21
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06310369
What this trial is testing

Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer

Who this might be right for
Bladder Cancer
European Organisation for Research and Treatment of Cancer - EORTC 50
Large-scale testing (Phase 3)Ended earlyNCT01438112
What this trial is testing

Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer

Who this might be right for
Transitional Cell CarcinomaBladder CancerCarcinoma in Situ+1 more
CG Oncology, Inc. 22
Early research (Phase 1)Looking for participantsNCT05519241
What this trial is testing

A Phase I Intravesical PPM Therapy for NMIBC

Who this might be right for
Non-muscle-invasive Bladder Cancer
VA Office of Research and Development 29
Testing effectiveness (Phase 2)Study completedNCT04498702
What this trial is testing

Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG Therapy

Who this might be right for
Non-muscle Invasive Bladder Cancer
Jiangsu Yahong Meditech Co., Ltd aka Asieris 41
Not applicableStudy completedNCT01304173
What this trial is testing

Retrospective Chart Review of Valstar

Who this might be right for
Carcinoma in Situ of Bladder
Endo USA Inc., a Keenova Therapeutics Company 113
Large-scale testing (Phase 3)Looking for participantsNCT06319820
What this trial is testing

Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

Who this might be right for
Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC 641
Large-scale testing (Phase 3)Active Not RecruitingNCT06111235
What this trial is testing

Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Who this might be right for
Non Muscle Invasive Bladder CancerUrologic CancerBladder Cancer+1 more
CG Oncology, Inc. 367
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06630871
What this trial is testing

A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.

Who this might be right for
NMIBC
Fujian Medical University Union Hospital 40
Testing effectiveness (Phase 2)Study completedNCT02307487
What this trial is testing

Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients

Who this might be right for
Bladder CancerNeoplasmsUrinary Bladder Diseases+1 more
UroGen Pharma Ltd. 14
Not applicableEnded earlyNCT01314664
What this trial is testing

A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC)

Who this might be right for
Bladder CancerCIS
Endo USA Inc., a Keenova Therapeutics Company 15
Testing effectiveness (Phase 2)Looking for participantsNCT07646145
What this trial is testing

Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer

Who this might be right for
Non-Muscle-Invasive Bladder Cancer (NMIBC)
Shanxi Province Cancer Hospital 30
Large-scale testing (Phase 3)WithdrawnNCT07313891
What this trial is testing

Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT

Who this might be right for
Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)Bladder (Urothelial, Transitional Cell) CancerUrothelial Carcinoma Bladder+1 more
Relmada Therapeutics, Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT07747740
What this trial is testing

Sequential Gemcitabine Plus Docetaxel Versus Gemcitabine Plus Mitomycin C for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer

Who this might be right for
Non-Muscle-Invasive Bladder CancerBCG-Unresponsive Bladder Cancer
Blokhin's Russian Cancer Research Center 228
Early research (Phase 1)WithdrawnNCT05259397
What this trial is testing

PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Who this might be right for
Bladder Cancer
Pfizer
Not applicableAvailableNCT06443944
What this trial is testing

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

Who this might be right for
Non-Muscle Invasive Bladder CancerUrothelial CarcinomaUrologic Cancer+1 more
CG Oncology, Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT05943379
What this trial is testing

RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects

Who this might be right for
NMIBC
RemeGen Co., Ltd. 85
Not applicableUnknownNCT05864599
What this trial is testing

External Validation of Uromonitor as a Biomarker for Optimization of NMIBC Management by the CUETO Group

Who this might be right for
Non-muscle-invasive Bladder Cancer
Pharmalink 600
Not applicableLooking for participantsNCT07495072
What this trial is testing

Early vs Delayed Intravesical Blad-Care During BCG Therapy

Who this might be right for
Urinary Bladder NeoplasmsBCG-Induced Cystitis
BLAD-HYA Group 56
Testing effectiveness (Phase 2)WithdrawnNCT04040725
What this trial is testing

Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression

Who this might be right for
Bladder Cancer
Dana-Farber Cancer Institute
Next Page